These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
253 related items for PubMed ID: 28275520
21. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, Mariappan P, Palou Redorta J, Stenzl A, van Velthoven R, Zaak D. Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887 [Abstract] [Full Text] [Related]
22. Comparison of staging MRI to re-resection for localised bladder cancer: Narrative review. Klempfner H, Anderson P. BJUI Compass; 2024 Jul; 5(7):651-661. PubMed ID: 39022656 [Abstract] [Full Text] [Related]
23. Additional oncological benefit of photodynamic diagnosis with blue light cystoscopy in transurethral resection for primary non-muscle-invasive bladder cancer: A comparative study from experienced institutes. Miyake M, Nishimura N, Nakahama T, Nishimoto K, Oyama M, Matsushita Y, Miyake H, Fukuhara H, Inoue K, Kobayashi K, Matsumoto H, Matsuyama H, Fujii T, Hirao Y, Fujimoto K. BJUI Compass; 2023 May; 4(3):305-313. PubMed ID: 37025476 [Abstract] [Full Text] [Related]
24. Transurethral resection of the bladder tumour (TURBT) for non-muscle invasive bladder cancer: basic skills. Furuse H, Ozono S. Int J Urol; 2010 Aug; 17(8):698-9. PubMed ID: 20649827 [Abstract] [Full Text] [Related]
25. Perioperative outcomes of transurethral resection for t1 bladder tumors: quality evaluation based on patient, tumor and surgeon criteria. Bebane S, Denize J, Goujon A, Meria P, Verine J, Mongiat-Artus P, Desgrandchamps F, Masson-Lecomte A. World J Urol; 2021 Nov; 39(11):4159-4165. PubMed ID: 34160681 [Abstract] [Full Text] [Related]
26. Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy. Palou-Redorta J, Solsona E, Angulo J, Fernández JM, Madero R, Unda M, Martínez-Piñeiro JA, Portillo J, Chantada V, Moyano JL. Actas Urol Esp; 2016 Nov; 40(6):370-7. PubMed ID: 26922518 [Abstract] [Full Text] [Related]
29. Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non-muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Trial. Yu G, Rice S, Heer R, Lewis R, Vadiveloo T, Mariappan P, Penegar S, Clark E, Tandogdu Z, Hall E, Vale L. Eur Urol Open Sci; 2023 Jul; 53():67-77. PubMed ID: 37441343 [Abstract] [Full Text] [Related]
31. The clinical significance of a second transurethral resection for T1 high-grade bladder cancer: Results of a prospective study. Shim JS, Choi H, Noh TI, Tae JH, Yoon SG, Kang SH, Bae JH, Park HS, Park JY. Korean J Urol; 2015 Jun; 56(6):429-34. PubMed ID: 26078839 [Abstract] [Full Text] [Related]
33. Transurethral en bloc resection with monopolar current for non-muscle invasive bladder cancer based on TNM system. Yang Y, Liu C, Yang X, Wang D. Transl Cancer Res; 2020 Apr; 9(4):2210-2219. PubMed ID: 35117581 [Abstract] [Full Text] [Related]
34. Time between first and second transurethral resection of bladder tumors in patients with high-grade T1 tumors: is it a risk factor for residual tumor detection? Süer E, Özcan C, Baltacı S, Gülpınar Ö, Burgu B, Haliloğlu A, Bedük Y. Urol Int; 2013 Apr; 91(2):182-6. PubMed ID: 23751593 [Abstract] [Full Text] [Related]
35. The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results. Naito S, Algaba F, Babjuk M, Bryan RT, Sun YH, Valiquette L, de la Rosette J, CROES Narrow Band Imaging Global Study Group. Eur Urol; 2016 Sep; 70(3):506-15. PubMed ID: 27117749 [Abstract] [Full Text] [Related]
36. Blue light transurethral resection and biopsy of bladder cancer with hexaminolevulinate: Histopathological characteristics and recurrence rates in a single UK centre study. Chan K, Hampson A, Hayes J, Rabinowitz J, Vasdev N. BJUI Compass; 2023 Sep; 4(5):568-574. PubMed ID: 37636209 [Abstract] [Full Text] [Related]
38. [Clinical significance of residual tumors at repeat transurethral resection in patients with T1 bladder cancer]. Chen JC, Li T, Ning XH, Peng SH, Wang JY, Qi NN, Cai L, Gong K. Zhonghua Yi Xue Za Zhi; 2016 Apr 12; 96(14):1124-7. PubMed ID: 27095782 [Abstract] [Full Text] [Related]
39. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden. Rose JB, Armstrong S, Hermann GG, Kjellberg J, Malmström PU. BJU Int; 2016 Jun 12; 117(6B):E102-13. PubMed ID: 26305667 [Abstract] [Full Text] [Related]
40. Prediction of histological stage based on cystoscopic appearances of newly diagnosed bladder tumours. During VA, Sole GM, Jha AK, Anderson JA, Bryan RT. Ann R Coll Surg Engl; 2016 Nov 12; 98(8):547-551. PubMed ID: 27502337 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]